Mutual of America Capital Management LLC Sells 952 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mutual of America Capital Management LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,030 shares of the medical research company’s stock after selling 952 shares during the quarter. Mutual of America Capital Management LLC’s holdings in IQVIA were worth $4,869,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Lazard Asset Management LLC grew its position in IQVIA by 0.9% during the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the period. Canada Pension Plan Investment Board grew its position in IQVIA by 6.4% during the first quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock valued at $807,183,000 after buying an additional 193,304 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares during the last quarter. Capital Research Global Investors lifted its holdings in IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after purchasing an additional 143,533 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after purchasing an additional 1,597,003 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 1.0 %

Shares of IQV opened at $242.12 on Friday. The firm’s 50 day simple moving average is $240.60 and its 200 day simple moving average is $234.07. The company has a market capitalization of $44.14 billion, a P/E ratio of 33.08, a P/E/G ratio of 2.25 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $2.22 earnings per share. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. UBS Group upped their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Truist Financial upped their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.